• 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Vignot S Lefebvre C Frampton


    [53] Vignot S, Lefebvre C, Frampton GM, Meurice G, Yelensky R, Palmer G, et al. Compar-ative analysis of primary tumour and matched metastases in colorectal cancer  patients: evaluation of concordance between genomic and transcriptional profiles.
    [54] Jesinghaus M, Wolf T, Pfarr N, Muckenhuber A, Ahadova A, Warth A, et al. Distinc-tive spatiotemporal stability of somatic mutations in metastasized microsatellite-stable colorectal cancer. Am J Surg Pathol 2015 Aug;39(8):1140–7.
    [55] Siyar Ekinci A, Demirci U, Cakmak Oksuzoglu B, Ozturk A, Esbah O, Ozatli T, et al. KRAS discordance between primary and metastatic tumor in patients with meta-static colorectal carcinoma. J BUON 2015;20(1):128–35.
    [56] Lau KS, Lam KO, Choy TS, Shek WH, Chung LP, Leung TW. Discordant RAS Status Be-tween Primary and Metastatic Colorectal Cancer and Predicted Pattern of Metasta-ses, 26; 2015 Annals of Oncology. [46 p]. [57] Lee KH, Kim JS, Lee CS, Kim JY. KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers. J Surg Oncol 2015 Jun;111(8): 1059–64.
    [63] Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, et al. Com-parative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 2014 Aug 28;15(8): 454.
    [66] Miglio U, Mezzapelle R, Paganotti A, Allegrini S, Veggiani C, Antona J, et al. Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay. Pathol Res Pract 2013 Apr;209(4):233–6.
    [67] Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M, et al. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN 1\'-hydroxy Midazolam in primary tumors and corresponding metastases in colorectal cancer. Mod Pathol 2013 Aug 31;26:302.
    [69] Vermaat JS, Nijman IJ, Koudijs MJ, Gerritse FL, Scherer SJ, Mokry M, et al. Primary colorectal cancers and their subsequent hepatic metastases are genetically differ-ent: implications for selection of patients for targeted treatment. Clin Cancer Res 2012 Feb;18(3):688–99.
    [70] Knijn N, Mekenkamp LJM, Klomp M, Vink-Borger ME, Tol J, Teerenstra S, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver me-tastases in 305 colorectal cancer patients. Br J Cancer 2011 Mar;104(6):1020–6.
    [71] Park JH, Han S-W, Oh D-Y, Im S-A, Jeong S-Y, Park KJ, et al. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metasta-ses in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 2011;68(4):1045–55. [72] Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, et al. Het-erogeneity of KRAS status may explain the subset of discordant KRAS status be-tween primary and metastatic colorectal cancer. Dis Colon Rectum 2011 Sep;54
    [73] Baldus SE, Schaefer K-L, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal ad-enocarcinomas and their corresponding metastases. Clin Cancer Res 2010 Feb;16 (3):790–9.
    [74] Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S, et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 2010 May;17(5):1429–34.
    [75] Mariani P, Lae M, Degeorges A, Cacheux W, Lappartient E, Margogne A, et al. Con-cordant analysis of KRAS status in primary colon carcinoma and matched metasta-sis. Anticancer Res 2010 Oct;30(10):4229–35. [76] Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in met-astatic colorectal cancer patients. Ann Oncol Off J Eur Soc Med Oncol 2009 Jan;20
    [77] Cejas P, Lopez-Gomez M, Aguayo C, Madero R, de Castro Carpeno J, Belda-Iniesta C, et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 2009 Dec;4(12):e8199. [78] Garm Spindler K-L, Pallisgaard N, Rasmussen AA, Lindebjerg J, Andersen RF, Cruger D, et al. The importance of KRAS mutations and EGF61ANG polymorphism to the
    effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol 2009 May;20(5):879–84. [79] Molinari F, Martin V, Saletti P, De Dosso S, Spitale A, Camponovo A, et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 2009 Apr 7;100(7): 1087–94.
    [80] Gattenlöhner S, Etschmann B, Kunzmann V, Thalheimer A, Hack M, Kleber G, et al. Concordance of KRAS/BRAF mutation status in metastatic colorectal cancer before and after anti-EGFR therapy. J Oncol 2009 Mar 10;2009:831626.